This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 May 2012

Jazz Pharmaceuticals to Acquire EUSA Pharma

Jazz Pharmaceuticals and EUSA Pharma have announced that Jazz Pharmaceuticals has agreed to acquire the specialty pharmaceutical company for $650 million in cash and a potential $50 million milestone payment.

Specialty biopharmaceutical company Jazz Pharmaceuticals is to acquire pharmaceutical outfit EUSA Pharma, the companies have announced.


The two firms have now signed a definitive agreement, under which Jazz Pharmaceuticals will pay $650 million in cash to acquire the company, which has headquarters in the US and the UK.


There is also the potential for an additional $50 million milestone payment if EUSA Pharma's lead product, Erwinaze (asparaginase Erwinia chrysanthemi), achieves a particular sales target in the US in 2013.


The therapy is designed to treat acute lymphoblastic leukemia and is one of a number of oncology products marketed directly in the US and Europe by EUSA Pharma.


Related News